Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics (Nasdaq: AKTX) launched a new CEO Corner platform on Oct 22, 2025 to deliver expanded perspective on press releases, corporate developments and pipeline progress.
The video platform features Abizer Gaslightwala, President and CEO, and allows interested parties to ask questions and submit topics for future videos. The CEO Corner is accessible on the company website.
Akari Therapeutics (Nasdaq: AKTX) announced a registered direct offering of 3,125,000 ADS at $0.80 per ADS, representing gross proceeds of approximately $2.5 million. In a concurrent private placement the company will issue unregistered Series E and Series F warrants, each to purchase up to 3,125,000 ADS at an exercise price of $0.98. Series E warrants: exercisable on shareholder approval and five-year term; Series F warrants: exercisable on shareholder approval and 30-month term. The offering is expected to close on or about October 16, 2025. Net proceeds are intended for working capital, general corporate purposes, and continued R&D focused on the novel ADC payload.
The ADSs are offered under an effective Form S-3 shelf registration (File No. 333-289056) declared effective July 31, 2025; the warrants and underlying ADSs are unregistered.
Akari Therapeutics (Nasdaq: AKTX) filed two provisional patent applications with the USPTO on Oct 9, 2025 to broaden intellectual property around its novel spliceosome‑modulating payload PH1. One filing claims PH1's immuno‑oncology mode of action via spliceosome modulation; the second claims combination therapies pairing PH1 ADCs with checkpoint inhibitors, citing preclinical synergy. These filings build on a late‑September provisional covering alternative splicing targeting and are intended to protect disclosures planned for an oral presentation at SITC on Nov 9, 2025. The release highlights AKTX‑101 (Trop2‑PH1 ADC) and future programs including AKTX‑102 as part of the expanding PH1 ADC pipeline.
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for an oral presentation at the 40th Annual SITC Meeting on Nov 5-9, 2025 in National Harbor, MD. The oral talk, titled "A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity," will be presented by Satyajit Mitra, Ph.D. on Sunday, Nov 9, 2025 at 11:05 AM ET in the Potomac Ballroom. A related poster will be presented on Friday, Nov 7, 2025 in Prince George ABC Exhibit Halls. For more details see sitcancer.org.
Akari Therapeutics (NASDAQ: AKTX) has announced promising preclinical data for its novel ADC spliceosome modulating payload, PH1, targeting hormone refractory prostate cancer. The data demonstrates PH1's ability to suppress AR-V7 receptor levels, which drives metastatic castration resistant prostate cancer (mCRPC) progression.
The research showed PH1's effectiveness in both hormone-refractory and hormone-sensitive prostate cancer models. In hormone-sensitive cases, PH1 showed additive effects when combined with existing treatments like Xtandi and Erleada. This suggests potential for developing first-line combination therapies and addressing the significant unmet need in ARPI-resistant cases, where current treatment options are limited.
Akari Therapeutics (Nasdaq: AKTX) has filed a provisional patent application with the USPTO for its novel antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1 for cancer treatment. The patent covers the platform's unique mechanism of modulating alternative splicing within cancer cells.
The technology targets cancer cells' ability to hijack alternative splicing (AS) processes, which affects tumor formation, growth, and metastasis. The PH1 payload demonstrates potential in disrupting cancer cell survival mechanisms across multiple types of cancers, including those resistant to current therapies.
The patent strengthens Akari's intellectual property portfolio and supports the development of their ADC programs, including AKTX-101 (Trop2 ADC with PH1 payload) and AKTX-102 (undisclosed target).
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on payload antibody drug conjugates (ADCs), will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Abizer Gaslightwala will deliver a presentation and conduct one-on-one meetings with registered investors. The presentation will be available via video webcast starting September 5, 2025, at 7:00 AM ET for registered attendees and will remain accessible on the company's website for 90 days.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025 at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment.
The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology company focused on developing novel Antibody Drug Conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech virtual event.
The company's President and CEO, Abizer Gaslightwala, will present on Tuesday, August 19, 2025, at 2:00 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, has released a Virtual Investor "What This Means" segment featuring CEO Abizer Gaslightwala. The presentation focuses on the company's novel spliceosome modulator payload, PH1, which is being developed as part of their antibody drug conjugates (ADCs) platform for cancer treatment.
During the segment, Gaslightwala discussed ongoing research efforts to understand how the PH1 payload can disrupt key drivers of cancer cell growth, highlighting the company's commitment to advancing their oncology pipeline.